← Back to Search

Cytokine

Pembrolizumab for Renal Cell Carcinoma

Phase 1

Waitlist Available

Led By Scott S. Tykodi

Research Sponsored by University of Washington

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at baseline and every 3 months

Awards & highlights

Study Summary

This trial is testing the side effects and best dose of aldesleukin when given with pembrolizumab to treat patients with kidney cancer.

Eligible Conditions

Renal Cell Carcinoma
Kidney Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at baseline and every 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at baseline and every 3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline and every 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of adverse events

Secondary outcome measures

Anti-tumor activity

Change in performance status

Disease control rate (DCR)

+2 more

Other outcome measures

Absolute numbers of effector T cells (Teff)

Absolute numbers of regulatory T cells (Treg)

Chromosomal copy number alterations

+3 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (pembrolizumab, aldesleukin)Experimental Treatment2 Interventions

Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Patients also receive aldesleukin subcutaneously (SC) 5 days per week for 6 weeks; or aldesleukin IV on days 2-6 of pembrolizumab cycles 1 and 2. Pembrolizumab treatment repeats every 3 weeks for 4 cycles per treatment course in the absence of clinical disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

2017

Completed Phase 2

~2010

Aldesleukin

2012

Completed Phase 4

~1620

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor

1,747 Previous Clinical Trials

1,847,373 Total Patients Enrolled

Merck Sharp & Dohme LLCIndustry Sponsor

3,899 Previous Clinical Trials

5,062,856 Total Patients Enrolled

Prometheus LaboratoriesIndustry Sponsor

26 Previous Clinical Trials

4,790 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What therapeutic purpose does Pembrolizumab typically serve?

"Pembrolizumab is frequently used to address malignant neoplasms, though can also be beneficial for cases of unresectable melanoma and microsatellite instability high. For those whose cancer has progressed after chemotherapy treatments, pembroilzumab may present a viable option."

Answered by AI

Has Pembrolizumab received official authorization for medicinal use?

"Due to the limited clinical data available, our team has rated Pembrolizumab's safety as a 1 on a scale from 1 to 3. This is due to it being in its early Phase 1 stages of testing."

Answered by AI

How many individuals are being administered treatment through this trial?

"Affirmative. According to the clinicaltrials.gov page, this clinical trial is presently enrolling participants, with 15 individuals sought from one location since its inception on August 28th 2018 and last update October 5th 2022."

Answered by AI

Are there any opportunities left to participate in this experiment?

"Affirmative. Clinicaltrials.gov has noted that this clinical trial, originally posted on August 28th 2018, is actively seeking participants and was last altered on October 5th 2022."

Answered by AI

To what extent have there been prior examinations involving Pembrolizumab?

"At the present time, there are 1,016 medical studies actively utilizing Pembrolizumab with 126 trials in Phase 3. Despite a large concentration of these experiments based out of Nashville, Tennessee; 36162 different sites globally have active research being conducted for this medication."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

2018. "Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03260504.